




RealRate

PHARMACEUTICAL 2022

Minerva Neurosciences Inc. Rank 389 of 466





RealRate

PHARMACEUTICAL 2022

Minerva Neurosciences Inc. Rank 389 of 466



The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 200% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 127% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	62,201
Cost of Goods Sold	0
Intangible Assets	14,869
Liabilities, Current	2,819
Liabilities, Non-Current	0
Other Assets	51
Other Compr. Net Income	0
Other Expenses	4,524
Other Liabilities	66,327
Other Net Income	-16
Other Revenues	0
Property and Equipment	0
Research and Development	32,039
Selling, General and Administrative Expense	13,327

Output Variable	Value in 1000 USD
Assets	77,122
Liabilities	69,146
Expenses	49,890
Revenues	0
Stockholders Equity	7,976
Net Income	-49,906
Comprehensive Net Income	-49,906
Economic Capital Ratio	-49%